We report membranous nephropathy in a 61-year-old man after allogeneic hematopoietic stem cell transplant without chronic graft-versus-host disease. A diagnosis of acute myeloid leukemia was made, and the patient received hematopoietic stem cell transplants, twice, from different donors. The first donor was his brother and the second donor was an unrelated man. Human leukocyte antigens between...

Bronchiolitis obliterans (BO) and bronchiolitis obliterans organizing pneumonia (BOOP) are late-onset non-infectious pulmonary complications (LONIPCs) following allogeneic hematopoietic stem cell transplantation (HSCT). In the present study 10 of 197 conventionally prepared stem cell recipients developed BOOP after 365 days and 6 patients developed BO 333 days post-transplant. No BOOP or BO was...

The first hematopoietic stem cell transplantation (HSCT) program in Latin America started 1979 at the federal university hospital Curitiba, Paraná, Brazil. Over years, number of centers performing transplants our country has increased tremendously, generating need to know results this treatment modality. Understanding HSCT scenario Brazil is still challenging, since not all Brazilian report dat...

Somatic tissue engraftment was studied in BXSB mice treated with mesenchymal stem cell transplantation. Hosts were conditioned with nonlethal radiation prior to introducing donor cells from major histocompatibility complex-matched green fluorescent protein transgenic mice. Transplant protocols differed for route of injection, ie, intravenous (i.v.) versus intraperitoneal (i.p.), and source of m...

BACKGROUND Long-term outcome after hematopoietic stem cell transplantation including late transplant-related events is of increasing interest. The aim of this study was to evaluate the incidence of cardiovascular events after allogeneic HSCT and to search for their risk factors. DESIGN AND METHODS This is a retrospective multicenter European Group of Blood and Marrow Transplantation (EBMT) an...

PURPOSE Previous trials of recombinant human erythropoietin (rHuEpo) therapy after autologous hematopoietic stem cell transplantation have administered very high doses of i.v. rHuEpo starting on day 1 and continuing for 1-2 months until erythroid engraftment and have shown no benefit of rHuEpo therapy. We sought to establish a more effective use of rHuEpo in this setting. EXPERIMENTAL DESIGN ...

Introduction: The use of cord stem cells, as a cell source for bone marrow reconstruction in patient under hematopoietic stem cell transplantation is enhancing. The amount of CD34+cells collected from cord blood compared to peripheral blood and bone marrow are less, but their collectionprocesure is easier. Delay in freezing has negative effect on cells surveillance and reduce their ability in ...

Major histocompatibility class I deficiency, due to genetic lesions in TAP1, TAP2, TAPBP, or B2M, manifests with recurrent sinopulmonary infections and granulomatous skin ulceration, is predominately treated antimicrobial prophylaxis chest physiotherapy. One previous report of hematopoietic stem cell transplantation has been described the literature, demonstrating cure immune defect without sig...